SCHEMBL1789532

SCHEMBL1789532

NC(=O)Cc1cccc(Nc2nccc(-c3c(-c4cccc(NC(=O)Cc5ccccc5)c4)nc4ccccn34)n2)c1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IGF1R P08069 16/20 0.62
EGFR P00533 9/20 0.62
ERBB2 P04626 8/20 0.62
PTK2 Q05397 3/20 0.62
CDK19 Q9BWU1 2/20 0.62
KDR P35968 6/20 0.59
RET P07949 5/20 0.59
STK3 Q13188 5/20 0.59
MAP4K5 Q9Y4K4 5/20 0.59
CSF1R P07333 4/20 0.59
MAP4K2 Q12851 4/20 0.59
FLT1 P17948 3/20 0.59
PRKD3 O94806 4/20 0.58
MAP4K4 O95819 4/20 0.58
LCK P06239 4/20 0.58
FYN P06241 4/20 0.58
TAOK1 Q7L7X3 4/20 0.58
AURKB Q96GD4 4/20 0.58
INSR P06213 4/20 0.58
AURKA O14965 3/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1876273 0.94 IGF1R (0.63) IGF1REGFRERBB2PTK2CDK19
SCHEMBL1789889 0.92 IGF1R (0.64) IGF1REGFRERBB2PTK2CDK19
SCHEMBL1788996 0.91 IGF1R (0.57) IGF1REGFRERBB2PTK2CDK19
SCHEMBL1788382 0.90 IGF1R (0.66) IGF1REGFRERBB2PTK2CDK19
SCHEMBL1790035 0.89 IGF1R (0.70) IGF1REGFRERBB2PTK2CDK19
SCHEMBL1790678 0.88 IGF1R (0.80) IGF1REGFRERBB2PTK2CDK19
SCHEMBL1789122 0.88 IGF1R (0.79) IGF1REGFRERBB2PTK2CDK19
SCHEMBL1788924 0.88 IGF1R (0.79) IGF1REGFRERBB2KDRRET
SCHEMBL1792604 0.88 IGF1R (0.59) IGF1REGFRERBB2PTK2CDK19
SCHEMBL1788249 0.88 IGF1R (0.61) IGF1REGFRERBB2PTK2CDK19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9051315-B2 Imidazopyridines as a novel scaffold for multi-targeted kinase inhibition ABBVIE INC. (US) 2015-06-09 US claimed
EP-2496574-A1 IMIDAZOPYRIDINES AS A NOVEL SCAFFOLD FOR MULTI-TARGETED KINASE INHIBITION Abbott Laboratories (US) 2012-09-12 EP claimed
US-20110124632-A1 IMIDAZOPYRIDINES AS A NOVEL SCAFFOLD FOR MULTI-TARGETED KINASE INHIBITION ABBOTT LABORATORIES (US) 2011-05-26 US claimed
WO-2011053476-A1 IMIDAZOPYRIDINES AS A NOVEL SCAFFOLD FOR MULTI-TARGETED KINASE INHIBITION ABBOTT LABORATORIES (US) 2011-05-05 WO claimed
US-9051315-B2 Imidazopyridines as a novel scaffold for multi-targeted kinase inhibition ABBVIE INC. (US) 2015-06-09 US disclosed
EP-2496574-A1 IMIDAZOPYRIDINES AS A NOVEL SCAFFOLD FOR MULTI-TARGETED KINASE INHIBITION Abbott Laboratories (US) 2012-09-12 EP disclosed
US-20110124632-A1 IMIDAZOPYRIDINES AS A NOVEL SCAFFOLD FOR MULTI-TARGETED KINASE INHIBITION ABBOTT LABORATORIES (US) 2011-05-26 US disclosed
WO-2011053476-A1 IMIDAZOPYRIDINES AS A NOVEL SCAFFOLD FOR MULTI-TARGETED KINASE INHIBITION ABBOTT LABORATORIES (US) 2011-05-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110124632-A1 IMIDAZOPYRIDINES AS A NOVEL SCAFFOLD FOR MULTI-TARGETED KINASE INHIBITION PACSIN2, MAP4K2, MAP3K6 IGF1R 937/4885EGFR 1013/4885ERBB2 323/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.